The 2-year local recurrence-free survival (LRFS) improved from 76.0% without adjuvant RT to 87.1% with it. Disease-free (DFS) ...

In July 2025, the FDA granted priority review for TAR-200 as therapy for patients with high-risk nonmuscle invasive bladder ...

Genitourinary cancers require individualized treatment plans based on type, stage, and patient health, utilizing imaging, ...

Radiation therapy could be an underused tool to reduce pelvic relapse risk for patients with locally advanced, ...

In a recent conversation with CURE, Hensley discussed the current treatment landscape of non-muscle-invasive bladder cancer, ...

Radiation therapy could be an underused tool to reduce pelvic relapse risk for patients with locally advanced, ...

Immunocompromised status may negatively affect survival outcomes in patients with bladder cancer, a study suggests.

(Nasdaq: URGN), a biotech company focused on developing and commercializing innovative solutions for urothelial and specialty cancers, today announced the publication of a comprehensive review of the ...

Adjuvant radiotherapy could substantially reduce risk for locoregional recurrence for patients with advanced muscle-invasive ...

Discover a study exploring how bladder cancer organoids advance personalised drug testing, reveal tumour heterogeneity, and ...

MIBC requires a multimodal treatment approach, with radical cystectomy as the gold standard and bladder-sparing options for select patients. Adjuvant immunotherapies, such as nivolumab and ...